Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07675876 | Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer(CS) | not yet recruiting | Phase 1 | 10 | Carcinex IncINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672431 |
| Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression |
| not yet recruiting |
| N/A |
| 24 |
| Barbara Ann Karmanos Cancer InstituteOTHER |
| 1 |
| Jun 29, 2026 |
| clinicaltrials |
| NCT07673393 | Improving Prognostication in Colon Cancer(MARBLE) | not yet recruiting | — | 400 | Universitaire Ziekenhuizen KU LeuvenOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07110233 | Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma | not yet recruiting | N/A | 64 | University of California, San FranciscoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07667608 | Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings | not yet recruiting | — | 120 | Assiut UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 36 | Hebei Medical University Fourth HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC(TRIBE) | not yet recruiting | Phase 3 | 140 | Fudan UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07206589 | Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial | not yet recruiting | N/A | 1,010 | Mayo ClinicOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07217990 | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer(NoCUT-BC) | not yet recruiting | Phase 1 / Phase 2 | 84 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07529080 | Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial | not yet recruiting | N/A | 142 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06770855 | Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC) | not yet recruiting | N/A | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | not yet recruiting | Phase 1 / Phase 2 | 76 | Telomir Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 23, 2026 | clinicaltrials |
| NCT07662005 | Objective Sleep Characteristics and Neoadjuvant Immunotherapy Response in Gastric/GEJ Cancer | not yet recruiting | — | 120 | West China Second University HospitalOTHER | 0 | Jun 23, 2026 | clinicaltrials |
| NCT07662252 | Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer(NEOSHED) | not yet recruiting | — | 186 | Federico II UniversityOTHER | 0 | Jun 23, 2026 | clinicaltrials |
| NCT07658872 | Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | not yet recruiting | Phase 2 | 120 | Sichuan UniversityOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07655661 | Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 52 | Ming LiuOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656337 | Effects of Direct Artery Injection on Prostate Cancer Drug Delivery and Tumor Uptake: Imaging-Based Prediction of Treatment Effectiveness(IAPSMA) | not yet recruiting | N/A | 10 | Lithuanian University of Health SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657273 | Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07647692 | Deep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT(GGN-Trajectory) | not yet recruiting | — | 4,750 | Peking University People's HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07644208 | PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07637786 | Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer | not yet recruiting | Phase 1 | 9 | Sichuan UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639801 | 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors | not yet recruiting | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07635654 | Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses(DELILA) | not yet recruiting | N/A | 43 | KU LeuvenOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07629193 | Liver Transplant for Hepatocellular Carcinoma(TH-CHC) | not yet recruiting | — | 562 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jun 5, 2026 | clinicaltrials |
| NCT07630246 | CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS(PAIR-LUNG) | not yet recruiting | — | 140 | Universidade Nova de LisboaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07627464 | Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy(ALTER-UC-011) | not yet recruiting | Phase 2 | 144 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07357948 | Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy(OMICHIR) | not yet recruiting | N/A | 150 | Institut CurieOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624214 | Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors | not yet recruiting | Phase 1 | 198 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07319104 | Liquid Biopsy in Early Colorectal Lesions(FECCO-BioBank) | not yet recruiting | — | 1,000 | University Hospital, MontpellierOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07621562 | Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer | not yet recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07584447 | Clinical Utility of Preoperative Thyroid GuidePx® Testing | not yet recruiting | — | 85 | University of CalgaryOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07618546 | A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors | not yet recruiting | N/A | 208 | Henan Cancer HospitalOTHER_GOV | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07610525 | Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial | not yet recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610629 | Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer(RA-A-NP) | not yet recruiting | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT07495579 | Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)(REVIVE) | not yet recruiting | Phase 2 | 146 | Asan Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | not yet recruiting | Phase 3 | 562 | SWOG Cancer Research NetworkNETWORK | 0 | May 27, 2026 | clinicaltrials |
| NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | not yet recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07605702 | The Canopy Cancer Collective Clinical Registry Protocol | not yet recruiting | — | 100,000 | Canopy Cancer Collective, LLCNETWORK | 1 | May 26, 2026 | clinicaltrials |
| NCT07602101 | Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma | not yet recruiting | Phase 2 | 33 | RenJi HospitalOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07583329 | Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy(V-COSMOS) | not yet recruiting | — | 160 | Cukurova UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07593040 | Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma(Moonlanding) | not yet recruiting | Phase 2 | 150 | Vall d'Hebron Institute of OncologyOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07600346 | A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery | not yet recruiting | — | 105 | The First Hospital of Jilin UniversityOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07592819 | A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)(PRODIGE 104 B) | not yet recruiting | N/A | 367 | Institut Paoli-CalmettesOTHER | 0 | May 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2026source: clinicaltrials